Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly
- PMID: 1907592
- DOI: 10.1055/s-2007-1003632
Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly
Abstract
The incidence of palpable goiters, the thyroid functional state and thyroid radioisotope uptake was analyzed retrospectively in 80 patients with acromegaly and 80 patients with prolactinomas. 71% of all patients with acromegaly had an enlargement of the thyroid (goiter); 49% of them had diffuse and 39% nodular goiters. The incidence of goiters in patients with prolactinomas from the same iodine deficient geographic region was only 35% (82% diffuse and 18% nodular). 17.5% of acromegalic patients underwent thyroid surgery before diagnosis of growth hormone excess. 17.5% of acromegalic patients with goiters had autonomous areas in their thyroids and 5% were clearly hyperthyroid. Goiters developed slightly more often in females (74%) than in males (67%). The mean preoperative growth hormone level was higher in acromegalic patients with goiter. The incidence of goiters was positively correlated with the documented time of elevated growth hormone concentration in serum. Two patients with exaggerated response of thyrotropin (TSH) (delta TSH greater than 20 mU/l) to the application of thyrotropin-releasing hormone (TRH) had no goiters. On the other hand most patients (61%) with goiters had a low TSH-response to TRH (delta TSH less than 10 mU/l) representing in part occult autonomy of thyroid function. No patient with prolactinoma has had previous thyroid surgery nor thyroid autonomy. One patient with prolactinoma suffered from Graves' disease and none of the acromegalic patients had this disease. We finally conclude that the elevation of growth hormone leads to increased incidence of euthyroid and hyperthyroid (autonomous) goiters independently of the influence of TSH.
Similar articles
-
Evolution of autonomy in idiopathic non-toxic goiter, evaluated by regional suppressibility of 99mTc-uptake and TSH response to TRH.Nuklearmedizin. 1976 Aug;15(4):197-200. Nuklearmedizin. 1976. PMID: 824625
-
Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland.Thyroid. 1999 Aug;9(8):791-6. doi: 10.1089/thy.1999.9.791. Thyroid. 1999. PMID: 10482372 Clinical Trial.
-
Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.J Clin Invest. 1979 Nov;64(5):1429-36. doi: 10.1172/JCI109601. J Clin Invest. 1979. PMID: 91625 Free PMC article.
-
TSH secretion and regulation in endemic goiter and endemic cretinism.Prog Clin Biol Res. 1983;116:119-30. Prog Clin Biol Res. 1983. PMID: 6304776 Review.
-
Evaluation and management of multinodular goiter.Otolaryngol Clin North Am. 1996 Aug;29(4):527-40. Otolaryngol Clin North Am. 1996. PMID: 8844728 Review.
Cited by
-
Acromegaly and thyroid.J Endocrinol Invest. 2002 Dec;25(11):930-1. doi: 10.1007/BF03344063. J Endocrinol Invest. 2002. PMID: 12553550 No abstract available.
-
Thyroid volume and function in patients with acromegaly living in iodine deficient areas.J Endocrinol Invest. 1997 Mar;20(3):134-7. doi: 10.1007/BF03346891. J Endocrinol Invest. 1997. PMID: 9186819
-
Growth hormone and insulin-like growth factor 1 affect the severity of Graves' disease.Endocrinol Diabetes Metab Case Rep. 2017 Jun 7;2017:17-0061. doi: 10.1530/EDM-17-0061. eCollection 2017. Endocrinol Diabetes Metab Case Rep. 2017. PMID: 28620496 Free PMC article.
-
Thyroid gland changes in patients with acromegaly.Arch Endocrinol Metab. 2020 May-Jun;64(3):269-275. doi: 10.20945/2359-3997000000247. Arch Endocrinol Metab. 2020. PMID: 32555993 Free PMC article.
-
Primary treatment of acromegaly with high-dose lanreotide: a case series.J Med Case Rep. 2010 Mar 8;4:85. doi: 10.1186/1752-1947-4-85. J Med Case Rep. 2010. PMID: 20211008 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials